|
業務類別
|
Biotechnology |
|
業務概覽
|
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole. |
| 公司地址
| 1300 El Camino Real, Suite 100, Menlo Park, CA, USA, 94025 |
| 電話號碼
| +1 650 331-9090 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.an2therapeutics.com |
| 員工數量
| 21 |
| Mr. Joshua M. Eizen, J.D. |
Chief Legal Officer and Chief Operating Officer |
美元 450.00K |
22/04/2026 |
| Dr. Sanjay Chanda, PhD |
Chief Development Officer |
-- |
22/04/2026 |
| Ms. Sarah Joanne Williams |
Vice President, Controller and Principal Accounting Officer |
-- |
29/01/2026 |
| Mr. Eric Easom |
Chairman of the Board, Chief Executive Officer and President |
美元 603.75K |
22/04/2026 |
| Ms. Lucy O. Day |
Chief Financial Officer |
美元 447.20K |
29/01/2026 |
|
|
| Mr. Joseph S. Zakrzewski |
Independent Director |
22/04/2026 |
| Dr. Melvin K. Spigelman,M.D. |
Independent Director |
22/04/2026 |
| Ms. Margaret M. FitzPatrick, M.A. |
Lead Independent Director |
22/04/2026 |
| Ms. Stephanie Wong |
Independent Director |
22/04/2026 |
| Mr. Eric Easom |
Chairman of the Board, Chief Executive Officer and President |
22/04/2026 |
| Mr. Kabeer Aziz |
Independent Director |
22/04/2026 |
| Mr. Gilbert Lynn Marks, M.D. |
Independent Director |
22/04/2026 |
| Ms. Patricia Martin |
Independent Director |
22/04/2026 |
| Dr. Rob Readnour, PhD |
Independent Director |
22/04/2026 |
|
|
|
|
